GB Sciences, Inc.
GBLX · OTC
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $62 | $70 | $47 |
| Gross Profit | -$1 | -$62 | -$70 | -$47 |
| % Margin | – | – | – | – |
| R&D Expenses | $262 | $490 | $821 | $0 |
| G&A Expenses | $1,159 | $1,672 | $1,869 | $2,002 |
| SG&A Expenses | $1,159 | $1,672 | $1,869 | $2,002 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$491 | -$821 | $0 |
| Operating Expenses | $1,421 | $1,672 | $1,869 | $2,002 |
| Operating Income | -$1,421 | -$1,672 | -$1,869 | -$2,002 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $59 | -$2,453 | $1,722 | -$1,331 |
| Pre-Tax Income | -$1,362 | -$4,125 | -$147 | -$3,333 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,362 | -$4,125 | -$531 | -$3,725 |
| % Margin | – | – | – | – |
| EPS | -0.004 | -0.012 | -0.002 | -0.012 |
| % Growth | 64.3% | -576.5% | 85.5% | – |
| EPS Diluted | -0.004 | -0.012 | -0.002 | -0.012 |
| Weighted Avg Shares Out | 396,729 | 357,721 | 317,622 | 285,191 |
| Weighted Avg Shares Out Dil | 396,729 | 357,721 | 317,622 | 285,191 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $219 | $179 | $475 | $1,285 |
| Depreciation & Amortization | $1 | $62 | $70 | $47 |
| EBITDA | -$1,420 | -$1,611 | -$1,799 | -$2,000 |
| % Margin | – | – | – | – |